P. Povarnina, Yulia N. Firsova, Anna V. Tallerova, Аrmen G. Mezhlumyan, Sergey V. Kruglov, Tatiana A. Antipova, Tatiana A. Gudasheva, Sergey B. Seredenin
{"title":"急性口服BDNF环4二肽模拟双(n -单琥珀酰-l -seryl- l-赖氨酸)六亚二胺对小鼠抑郁模型有活性","authors":"P. Povarnina, Yulia N. Firsova, Anna V. Tallerova, Аrmen G. Mezhlumyan, Sergey V. Kruglov, Tatiana A. Antipova, Tatiana A. Gudasheva, Sergey B. Seredenin","doi":"10.5772/intechopen.88244","DOIUrl":null,"url":null,"abstract":"Low-molecular mimetic BDNF GSB-106, which is a substituted dimeric dipeptide, bis(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide, was designed and synthesized in the V. V. Zakusov Research Institute of Pharmacology. The dipeptide activates TrkB, PI3K/AKT, and MAPK/ ERK. GSB-106 is being developed as a potential antidepressant. Its antidepressant activity was detected in a number of rodent tests (0.1–1.0 mg/kg, ip; 0.5–5.0 mg/kg, po). In the present study, GSB-106 was shown to completely eliminate the manifestation of anhedonia in the sucrose preference test and to increase disturbed hippocampal synaptogenesis at acute oral administration (0.1 mg/kg) after 10-day social defeat stress in C57Bl/6 mice.","PeriodicalId":209157,"journal":{"name":"Antidepressants - Preclinical, Clinical and Translational Aspects","volume":"35 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The BDNF Loop 4 Dipeptide Mimetic Bis(N-monosuccinyl-L-seryl-L-lysine)hexamethylenediamide Is Active in a Depression Model in Mice after Acute Oral Administration\",\"authors\":\"P. Povarnina, Yulia N. Firsova, Anna V. Tallerova, Аrmen G. Mezhlumyan, Sergey V. Kruglov, Tatiana A. Antipova, Tatiana A. Gudasheva, Sergey B. Seredenin\",\"doi\":\"10.5772/intechopen.88244\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Low-molecular mimetic BDNF GSB-106, which is a substituted dimeric dipeptide, bis(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide, was designed and synthesized in the V. V. Zakusov Research Institute of Pharmacology. The dipeptide activates TrkB, PI3K/AKT, and MAPK/ ERK. GSB-106 is being developed as a potential antidepressant. Its antidepressant activity was detected in a number of rodent tests (0.1–1.0 mg/kg, ip; 0.5–5.0 mg/kg, po). In the present study, GSB-106 was shown to completely eliminate the manifestation of anhedonia in the sucrose preference test and to increase disturbed hippocampal synaptogenesis at acute oral administration (0.1 mg/kg) after 10-day social defeat stress in C57Bl/6 mice.\",\"PeriodicalId\":209157,\"journal\":{\"name\":\"Antidepressants - Preclinical, Clinical and Translational Aspects\",\"volume\":\"35 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antidepressants - Preclinical, Clinical and Translational Aspects\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5772/intechopen.88244\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antidepressants - Preclinical, Clinical and Translational Aspects","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/intechopen.88244","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The BDNF Loop 4 Dipeptide Mimetic Bis(N-monosuccinyl-L-seryl-L-lysine)hexamethylenediamide Is Active in a Depression Model in Mice after Acute Oral Administration
Low-molecular mimetic BDNF GSB-106, which is a substituted dimeric dipeptide, bis(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide, was designed and synthesized in the V. V. Zakusov Research Institute of Pharmacology. The dipeptide activates TrkB, PI3K/AKT, and MAPK/ ERK. GSB-106 is being developed as a potential antidepressant. Its antidepressant activity was detected in a number of rodent tests (0.1–1.0 mg/kg, ip; 0.5–5.0 mg/kg, po). In the present study, GSB-106 was shown to completely eliminate the manifestation of anhedonia in the sucrose preference test and to increase disturbed hippocampal synaptogenesis at acute oral administration (0.1 mg/kg) after 10-day social defeat stress in C57Bl/6 mice.